Abstract
Background: Patients with psoriasis frequently experience anxiety, depression, and increased psychological distress in association with their disease. Previous work has shown that Dermatology Life Quality Index (DLQI) scores directly associate with measures of disease severity and parallel treatment response.
 Methods: Participants included new biologic initiations in 2018 in the CorEvitas Psoriasis registry with baseline and 6-month follow-up visits available. Logistic regressions resulted in adjusted odd ratios (OR) and 95% CIs for achievement of DLQI 0/1 for 7 US geographic regions. 
 Results: There were 737 new biologic initiations included in the study. Of these, 644 had DLQI > 0 at baseline. Baseline mean DLQI scores did not vary significantly among geographic regions. Overall, 42.7% of patients achieved DLQI 0/1 at 6-months. The Pacific region reported the smallest proportion achieving this target (26.9%) followed by the East South Central (ESC) (34.3%) and West South Central (WSC) (40.9%) with a range of 26.9-51.1% across all regions. In logistic regression models adjusted for age, sex, race, and BMI, the Pacific had 61% lower odds of achieving DLQI 0/1 compared to the Northeast.
 Conclusions: Improvement of DLQI scores at 6-months of treatment for psoriasis is not geographically uniform across the United States. Regions that had the lowest proportions of achieving PASI75 also had the lowest proportions of patients achieving DLQI 0/1; yet when fully adjusted only patients in the Pacific were less likely to achieve DLQI 0/1, suggesting factors beyond treatment response impact patient quality of life.
Highlights
There were 737 new biologic initiations in 2018 occurring at a CorEvitas visit that had a subsequent 6-month follow-up, 644 of whom had Dermatology Life Quality Index (DLQI) > 0 at baseline.[1]
In logistic regression models adjusted for age, sex, race, and BMI, the Pacific had 61% lower odds of achieving DLQI 0/1 compared to the Northeast (Odds Ratio 0.39, 95% CI: 0.210.71) (Table I)
In analyses stratified by biologic therapy class, patients in the Pacific and the East South Central (ESC) were less likely to achieve DLQI 0/1 compared to the Northeast among IL12/23 & IL-23 inhibitor initiators (Table II)
Summary
There were 737 new biologic initiations (mean age 50.3 years, 48.0% women) in 2018 occurring at a CorEvitas visit that had a subsequent 6-month follow-up, 644 of whom had DLQI > 0 at baseline.[1]. There were 737 new biologic initiations (mean age 50.3 years, 48.0% women) in 2018 occurring at a CorEvitas visit that had a subsequent 6-month follow-up, 644 of whom had DLQI > 0 at baseline.[1] Baseline mean DLQI scores did not vary significantly among geographic regions, p=0.072 (Table I).
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
